Thr300
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr300  -  AML1 iso8 (human)

Site Information
sPSVHPAtPIsPGRA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 454403

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 2 , 3 , 4 ) , mutation of modification site ( 2 , 3 , 4 )
Disease tissue studied:
leukemia ( 4 ) , chronic myelogenous leukemia ( 4 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
ERK1 (human) ( 4 ) , ERK2 (human) ( 4 )
Kinases, in vitro:
CDK1 (human) ( 2 ) , CDK2 (human) ( 2 ) , CDK6 (human) ( 2 )
Treatments:
PD98059 ( 4 ) , phorbol_ester ( 4 )

Downstream Regulation
Effects of modification on AML1 iso8:
protein degradation ( 2 , 3 )

References 

1

Yoshimi M, et al. (2012) Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation. Eur J Immunol 42, 1044-50
22531928   Curated Info

2

Biggs JR, et al. (2006) AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol Cell Biol 26, 7420-9
17015473   Curated Info

3

Biggs JR, et al. (2005) Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association. Mol Cancer Res 3, 391-401
16046550   Curated Info

4

Zhang Y, Biggs JR, Kraft AS (2004) Phorbol ester treatment of K562 cells regulates the transcriptional activity of AML1c through phosphorylation. J Biol Chem 279, 53116-25
15475366   Curated Info